Sivik Global Healthcare LLC Makes New $4.21 Million Investment in Bruker Corporation $BRKR

Sivik Global Healthcare LLC acquired a new position in shares of Bruker Corporation (NASDAQ:BRKR) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 65,000 shares of the medical research company’s stock, valued at approximately $4,209,000. Bruker comprises 2.6% of Sivik Global Healthcare LLC’s investment portfolio, making the stock its 17th largest holding.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. GAMMA Investing LLC raised its holdings in Bruker by 13.0% during the 3rd quarter. GAMMA Investing LLC now owns 5,373 shares of the medical research company’s stock valued at $348,000 after buying an additional 618 shares during the last quarter. Moody National Bank Trust Division bought a new stake in Bruker in the 3rd quarter worth $728,000. Sequoia Financial Advisors LLC bought a new stake in Bruker in the 2nd quarter worth $250,000. Tidal Investments LLC increased its position in shares of Bruker by 180.4% in the second quarter. Tidal Investments LLC now owns 29,092 shares of the medical research company’s stock valued at $1,751,000 after acquiring an additional 18,715 shares during the period. Finally, WINTON GROUP Ltd bought a new position in shares of Bruker during the second quarter valued at about $344,000. 79.52% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Bruker

In other news, VP Mark Munch sold 2,000 shares of Bruker stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $52.87, for a total transaction of $105,740.00. Following the transaction, the vice president directly owned 134,806 shares of the company’s stock, valued at $7,127,193.22. The trade was a 1.46% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 27.20% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on BRKR. Guggenheim boosted their price target on Bruker from $70.00 to $72.00 and gave the company a “buy” rating in a report on Thursday, October 1st. Zacks Research lowered Bruker from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, September 2nd. Leerink Partners boosted their target price on Bruker from $60.00 to $80.00 and gave the company an “outperform” rating in a research note on Tuesday, September 29th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Bruker in a research note on Monday, August 31st. Finally, Citigroup cut their target price on shares of Bruker from $60.00 to $53.00 and set a “hold” rating on the stock in a research note on Wednesday, August 5th. Two research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, five have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $59.79.

Bruker Stock Performance

Shares of NASDAQ BRKR traded down $0.26 during trading on Tuesday, reaching $55.99. 799,992 shares of the company traded hands, compared to its average volume of 2,354,364. The firm has a 50 day simple moving average of $58.48 and a 200-day simple moving average of $52.89. The stock has a market capitalization of $8.53 billion, a PE ratio of -80.01, a P/E/G ratio of 1.80 and a beta of 1.22. The company has a quick ratio of 0.92, a current ratio of 1.85 and a debt-to-equity ratio of 0.76. Bruker Corporation has a 52-week low of $32.37 and a 52-week high of $66.98.

Bruker (NASDAQ:BRKR) last announced its earnings results on Tuesday, August 4th. The medical research company reported $0.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.38 by $0.11. Bruker had a positive return on equity of 12.47% and a negative net margin of 2.35%. The business had revenue of $838.50 million for the quarter, compared to analysts’ expectations of $853.57 million. During the same period last year, the firm posted $0.32 earnings per share. The business’s revenue for the quarter was up 5.2% on a year-over-year basis. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Equities research analysts anticipate that Bruker Corporation will post 2.12 earnings per share for the current year.

Bruker Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, October 7th. Shareholders of record on Monday, September 21st were given a $0.05 dividend. The ex-dividend date was Monday, September 21st. This represents a $0.20 dividend on an annualized basis and a yield of 0.4%. Bruker’s dividend payout ratio is presently -28.57%.

Bruker Company Profile

Bruker Corporation develops and manufactures scientific instruments, analytical systems and related software used to study materials, chemicals, biological samples and industrial products. Its customers include academic and government research institutions, pharmaceutical and biotechnology companies, hospitals, environmental laboratories and industrial manufacturers.

The company’s portfolio includes nuclear magnetic resonance and electron paramagnetic resonance systems, mass spectrometers, X-ray instruments, microscopy and surface-analysis platforms, molecular spectroscopy systems, and analytical tools for proteomics, spatial biology, metabolomics and materials research.